pSLCAR-CD19-BBz Citations (4)

Originally described in: A High-Throughput Method for Characterizing Novel Chimeric Antigen Receptors in Jurkat Cells.
Bloemberg D, Nguyen T, MacLean S, Zafer A, Gadoury C, Gurnani K, Chattopadhyay A, Ash J, Lippens J, Harcus D, Page M, Fortin A, Pon RA, Gilbert R, Marcil A, Weeratna RD, McComb S Mol Ther Methods Clin Dev. 2020 Jan 31;16:238-254. doi: 10.1016/j.omtm.2020.01.012. eCollection 2020 Mar 13. PubMed Journal

---

Articles Citing pSLCAR-CD19-BBz

Articles
Engineering self-propelled tumor-infiltrating CAR T cells using synthetic velocity receptors. Johnston AC, Alicea GM, Lee CC, Patel PV, Hanna EA, Vaz E, Forjaz A, Wan Z, Nair PR, Lim Y, Chen T, Du W, Kim D, Nichakawade TD, Rebecca VW, Bonifant CL, Fan R, Kiemen AL, Wu PH, Wirtz D. bioRxiv [Preprint]. 2024 Mar 26:2023.12.13.571595. doi: 10.1101/2023.12.13.571595. PubMed
The CUL5 E3 ligase complex negatively regulates central signaling pathways in CD8(+) T cells. Liao X, Li W, Zhou H, Rajendran BK, Li A, Ren J, Luan Y, Calderwood DA, Turk B, Tang W, Liu Y, Wu D. Nat Commun. 2024 Jan 19;15(1):603. doi: 10.1038/s41467-024-44885-0. PubMed
Priming with LSD1 inhibitors promotes the persistence and antitumor effect of adoptively transferred T cells. Qiu F, Jiang P, Zhang G, An J, Ruan K, Lyu X, Zhou J, Sheng W. Nat Commun. 2024 May 21;15(1):4327. doi: 10.1038/s41467-024-48607-4. PubMed
BCMA/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma. Lu Q, Li H, Wu Z, Zhu Z, Zhang Z, Yang D, Tong A. J Nanobiotechnology. 2024 May 23;22(1):279. doi: 10.1186/s12951-024-02512-6. PubMed

If you have published an article using this material, please email us at to have your article added to this page.